Polymyositis complicating donor lymphocyte infusion after stem cell transplantation for relapsed chronic myeloid leukemia: report of a case and review of literature.
Polymyositis may occur along with other manifestations of chronic graft vs host disease after allogeneic bone marrow transplantation (BMT). Donor lymphocyte infusion (DLI) could produce durable remissions in relapsed patients with chronic myelogenous leukemia (CML) but it may contribute to the development of polymyositis. We report in this study a 25-year-old man who suffered from a relapse of CML 4 years after a sibling human leukocyte antigen-matched allogenic BMT. The patient developed polymyositis 18 months after DLI. Mini-pulse therapy with methylprednisolone was effective for his proximal weakness and elevated creatine phosphokinase. There was no relapse of symptoms of polymyositis on tapering of the medication.
Liu
Feng-Cheng
FC
Divisions of Rheumatology/Immunology/Allergy, Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan, Republic of China.
Chen
Chen-Hung
CH
Chao
Tsu-Yi
TY
D000328:Adult; D003131:Combined Modality Therapy; D005938:Glucocorticoids / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000628:therapy*; D017710:Lymphocyte Transfusion / Q000009:adverse effects*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D017285:Polymyositis / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D020551:Pulse Therapy, Drug; D012008:Recurrence; D033581:Stem Cell Transplantation / Q000009:adverse effects*
D005938:Glucocorticoids; D008775:Methylprednisolone